As of Sep 22
| +0.03 / +0.43%|
The 8 analysts offering 12-month price forecasts for Keryx Biopharmaceuticals Inc have a median target of 8.00, with a high estimate of 10.00 and a low estimate of 5.00. The median estimate represents a +15.11% increase from the last price of 6.95.
The current consensus among 9 polled investment analysts is to Hold stock in Keryx Biopharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.